<?xml version="1.0" encoding="UTF-8"?>
<p id="para3780">Since only a small proportion of patients with hepatitis B and C are ever diagnosed, the importance of screening and diagnostics need to be better emphasised. New approaches and tools are required for point-of-care diagnostics that are suitable for high-burden, low-resource countries. The 2018 establishment of a WHO Essential Diagnostics List
 <xref rid="bib426" ref-type="bibr">
  <sup>426</sup>
 </xref> is a welcome recognition of this importance. A greater focus is now needed on prequalification (ie, evaluating diagnostic tests with standardised protocols for their quality, performance, and safety to guide procurement decisions by actors such as WHO Member States or UN agencies) to ensure provision of high-quality diagnostics and clinical evidence for simplified management algorithms in settings where diagnostics are not available.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> We believe that governments should widely engage with all stakeholders, including individuals and organisations representing at-risk groups (eg, people who inject drugs, prisoners, and individuals with HIV), and also be liberal in approving and implementing new diagnostic devices.
</p>
